The State of UK and Israel DeepTech Investment

Having spent much of my career working at the intersection of science, technology, investment, and commercialization in both the UK and Israel, I am often asked whether the investment relationship between the two countries remains as strong as it was a decade ago.

My answer is unequivocally yes.

In fact, I would argue that the strategic rationale for UK investors to engage with Israeli DeepTech has never been stronger.

Over the past twenty-five years, I have had the privilege of working with some of the most innovative institutions in both ecosystems, including the Technion, Tel Aviv Sourasky Medical Center (Ichilov), and King's College London. Throughout that time, one pattern has remained remarkably consistent: Israel continues to produce an outsized number of globally relevant technology companies relative to its size.

What has changed is the nature of the opportunity.

A decade ago, much of the investor focus was on cybersecurity, enterprise software, and internet technologies. Today, the most compelling opportunities are increasingly found in DeepTech sectors where scientific excellence, engineering complexity, and long development cycles create substantial barriers to entry.

These include artificial intelligence, quantum technologies, advanced materials, defence technologies, digital health, medical devices, semiconductors, energy resilience, robotics, and industrial automation.

What makes Israel particularly attractive is the quality of the underlying innovation engine.

Institutions such as the Technion, the Weizmann Institute, Tel Aviv University, Hebrew University, and Ben-Gurion University continue to generate world-class science. Around them sits a highly sophisticated venture ecosystem, experienced entrepreneurs, and a culture that encourages ambitious problem-solving.

Importantly, many Israeli founders are now second- or third-time entrepreneurs. They have built companies before, navigated global markets, and understand how to engage international investors from day one.

For UK investors, this creates a particularly attractive proposition.

The UK has one of Europe's strongest DeepTech investment communities, with firms such as IP Group, Parkwalk Advisors, Oxford Science Enterprises, and Syncona helping build globally significant technology companies.

The challenge facing many UK investors is not access to capital, talent, or scientific research. It is finding sufficiently differentiated opportunities capable of delivering venture-scale returns.

Israel continues to offer exactly that.

One area attracting growing attention is defence and dual-use technology. The geopolitical environment of recent years has accelerated demand for solutions in autonomy, cybersecurity, sensing, battlefield intelligence, resilient communications, and energy security. Israeli companies often benefit from unusually deep operational insight into these domains, making them particularly attractive to international investors.

Healthcare is another area where I see increasing UK interest.

Israeli companies benefit from access to highly digitized healthcare systems, world-class clinicians, and an unusually collaborative environment for clinical validation. This creates opportunities in diagnostics, AI-enabled healthcare, medical devices, and digital therapeutics that align closely with UK investor priorities.

At the same time, the relationship is becoming more balanced.

Historically, many Israeli companies viewed London primarily as a source of capital. Increasingly, they see the UK as something more valuable: a gateway to customers, strategic partners, clinical validation environments, defence procurement pathways, and global markets.

This evolution is important.

The strongest UK-Israel relationships today are not simply investment transactions. They are long-term partnerships involving investors, corporations, universities, hospitals, government agencies, and entrepreneurs working together to accelerate innovation.

Of course, challenges remain.

The geopolitical environment creates uncertainty. DeepTech companies often require significant capital and patience. Regulatory requirements are becoming more complex. Investors must work harder than ever to separate genuine technological breakthroughs from hype.

Yet these challenges are precisely why DeepTech remains attractive.

When a company successfully navigates technical, regulatory, and commercial hurdles, it often emerges with substantial competitive advantages and defensible intellectual property.

Looking ahead, I believe the most successful UK investors will be those who develop a deeper understanding of the Israeli innovation ecosystem rather than viewing it solely as a source of deal flow.

Israel is not simply a startup nation.

It is increasingly a DeepTech nation.

For UK investors seeking differentiated technologies, world-class founders, and globally scalable opportunities, the ecosystem continues to offer some of the most compelling opportunities available anywhere in the world.

The opportunity is no longer discovering Israel.

The opportunity is building stronger bridges between two ecosystems that have far more in common than many people realize.